News Sentiment

PSTV sentiment intelligence

Plus Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.74 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.5% over one week, -11.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend inactive -11.0% over four weeks
Fair value -86.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 40
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
Market source 15
Investing.com 5
TradingView 5
GlobeNewswire 3
simplywall.st 3
MT Newswires 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 15
Deals and strategy 2
Guidance 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Stock Titan Direct company coverage

Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30

Plus Therapeutics (Nasdaq: PSTV) announced it will host a business update conference call and webcast on June 30, 2026, at 8:30 a.m. ET. Management plans to discuss the launch of its CNSide diagnostic, the integrated development plan for its lead drug Reyobiq, its CNS oncology st

Tone
Positive 71/100
Event
Market update
Published
23 Jun 2026 11:11
Source
Stock Titan
TradingKey Direct company coverage

Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Plus Therapeutics Inc (PSTV), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 2.81, ranking 186 out of 388 in the Biotechnology & Medical Research industry, and its beta value of

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 09:40
Source
TradingKey
TradingKey Direct company coverage

Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Plus Therapeutics Inc (PSTV) for fiscal year 2018, updated as of March 4, 2025. It categorizes revenue by business segments, including Consumable, Other products, and Device, and by geographic regions, specifically Japan, Ame

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 06:40
Source
TradingKey